Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Histone deacetylase inhibitors as new cancer drugs

Marks, Paul A., Richon, Victoria M., Breslow, Ronald, Rifkind, Richard A. · 2001 · Current Opinion in Oncology

Abstract

Histone deacetylase inhibitors are potent inducers of growth arrest, differentiation, or apoptotic cell death in a variety of transformed cells in culture and in tumor bearing animals. Histone deacetylases and the family of histone acetyl transferases are involved in determining the acetylation of histones, which play a role in regulation of gene expression. Radiograph crystallographic studies reveal that the histone deacetylase inhibitors, suberoylanilide hydroxamic acid and trichostatin A, fit into the catalytic site of histone deacetylase, which has a tubular structure with a zinc atom at its base. The hydroxamic acid moiety of the inhibitor binds to the zinc. Histone deacetylase inhibitors cause acetylated histones to accumulate in both tumor and peripheral circulating mononuclear cells. Accumulation of acetylated histones has been used as a marker of the biologic activity of the agents. Hydroxamic acid-based histone deacetylase inhibitors limit tumor cell growth in animals with little or no toxicity. These compounds act selectively on genes, altering the transcription of only approximately 2% of expressed genes in cultured tumor cells. A number of proteins other than histones are substrates for histone deacetylases. The role that these other targets play in histone deacetylase inducement of cell growth arrest, differentiation, or apoptotic cell death is not known. This review summarizes the characteristics of a variety of inhibitors of histone deacetylases and their effects on transformed cells in culture and tumor growth in animal models. Several structurally different histone deacetylase inhibitors are in phase I or II clinical trials in patients with cancers.

Overview

Integrity signals

Registry

Crossref · 10.1097/00001622-200111000-00010

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Research works printed but not linked: 14

  1. Weidle, 2000, Anticancer Res, 20, 1471
  2. Kelly, 2001, Proc Amer Soc Clin Oncol, 20, 87a
  3. Zhu, 2001, Cancer Res, 61, 1327
  4. Gore, 2001, Proc Am Assoc Cancer Res, 42, 126
  5. Remiszewski, 2001, Proc Amer Assoc Cancer Res, 42, 927
  6. Su, 2000, Cancer Res, 60, 3137
  7. Nervi, 2001, Cancer Res, 61, 1247
  8. Lee, 2001, Cancer Res, 61, 931
  9. Han, 2000, Cancer Res, 60, 6068
  10. Marks, 2001, Clin Cancer Res, 7, 759
  11. Butler, 2000, Cancer Res, 60, 5165
  12. Butler, 2001, Clin Cancer Res, 7, 962
  13. Ferrara, 2001, Cancer Res, 61, 2
  14. Coffey, 2001, Cancer Res, 61, 3591

Cited by

See all 622

Metadata

Authors
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Columbia University (US)
Corresponding author
  • Marks, Paul A.
  • Richon, Victoria M.
  • Rifkind, Richard A.
Venue
Current Opinion in Oncology
Published
2001-11
Volume
13
Issue
6
Pages
477-483
ISSN
1040-8746 (ISSN-L)
OpenAlex
W2070437897
Cited by
531
References
51
Citations by year
2026: 2 · 2025: 6 · 2024: 2 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 5 · 2018: 11 · 2017: 9 · 2016: 14 · 2015: 14 · 2014: 11 · 2013: 24 · 2012: 23
FWCI
3.23
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
histone deacetylase inhibitors, histone acetylation, vorinostat, trichostatin A, hydroxamic acids, zinc binding, gene expression regulation, tumor growth inhibition, apoptosis, cell differentiation, growth arrest, non-histone substrates, anticancer drug development
MeSH terms
Animals, Cell Cycle, Cell Differentiation, Disease Models, Animal, Enzyme Inhibitors, Histone Deacetylases, Histones, Humans, Neoplasms, Tumor Cells, Cultured, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Apoptosis, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone deacetylase inhibitors as new cancer drugs. https://app.cochat.ai/papers/10.1097/00001622-200111000-00010
The paper
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001). Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology. https://doi.org/10.1097/00001622-200111000-00010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.